Can-Fite (CANF): Operating Sales Margin

Public company logo of Can-Fite BioPharma Ltd. (CANF)

The seamless operation of laboratories and partner facilities ensures a stable testing cycle. This chart on GURU.Markets displays the operating margin, while the -2402.90 metric confirms the current level. Bioscreening efficiency is increasing through the robotization of processes. Can-Fite BioPharma (CANF) revenues are based on licensing fees and the therapy of patients with oncology or psoriasis via adenosine receptors.

CANF - canfite.com Operating Profit Ratio over the range 07/04/2022 - 11/19/2026

Metric breakdowns and analytics for canfite.com (CANF)

- stock quotes and analyst forecast:
Fundamental company valuation:Can-Fite BioPharma Ltd, CANF
Finished products of Can-Fite BioPharma

Can-Fite BioPharma (CANF) is minimizing raw material shortages by diversifying its bioactive substance supply chains, thereby maintaining high profitability in the development of anti-tumor drugs. By analyzing the current operating margin, investors can assess the efficiency of the core business before debt and taxes, which allows them to determine the risk of overpaying for the asset or its potential undervaluation through a daily stress test of the model.